Heart shield: diabetes drug may protect breast cancer Patients' hearts during chemo
NCT ID NCT07245069
First seen Dec 08, 2025 · Last updated May 19, 2026 · Updated 27 times
Summary
This study tests whether dapagliflozin, a drug used for diabetes, can prevent heart damage caused by a common type of chemotherapy (anthracycline) in women with breast cancer. About 100 participants will take either dapagliflozin or a placebo daily during their chemo. Researchers will use heart ultrasounds and blood tests to see if the drug helps keep the heart and blood vessels healthy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Medical Centre Ljubljana
RECRUITINGLjubljana, 1000, Slovenia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.